Mineralys Therapeutics (MLYS) Insider Trading & Ownership → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free MLYS Stock Alerts $11.43 +0.29 (+2.60%) (As of 04:00 PM ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Mineralys Therapeutics (NASDAQ:MLYS) Insider Buying and Selling ActivityNumber OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$7.61 MNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$2.01 M Get MLYS Insider Trade Alerts Want to know when executives and insiders are buying or selling Mineralys Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MLYS Insider Buying and Selling by Quarter Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. Mineralys Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/12/2024Samsara Biocapital Gp, LlcMajor ShareholderBuy555,555$13.50$7,499,992.50 11/22/2023Jon CongletonCEOBuy4,250$5.97$25,372.50 9/6/2023Jon CongletonCEOBuy2,250$12.08$27,180.00 8/17/2023Jon CongletonCEOBuy2,250$12.10$27,225.00 8/11/2023David Malcom RodmaninsiderSell157,091$12.81$2,012,335.71 8/11/2023Jon CongletonCEOBuy2,000$12.89$25,780.00 (Data available from 1/1/2013 forward) MLYS Insider Trading Activity - Frequently Asked Questions Who is on Mineralys Therapeutics's Insider Roster? The list of insiders at Mineralys Therapeutics includes Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, L.P., and Samsara Biocapital Gp, Llc. Learn more on insiders at MLYS. Which Mineralys Therapeutics insiders have been buying company stock? The following insiders have purchased MLYS shares in the last 24 months: Adam Scott Levy ($100,000.00), Hbm Healthcare Investments (Ca ($5,000,000.00), Jon Congleton ($105,557.50), Ra Capital Management, L.P. ($20,000,000.00), and Samsara Biocapital Gp, Llc ($7,499,992.50). How much insider buying is happening at Mineralys Therapeutics? Insiders have purchased a total of 2,135,055 MLYS shares in the last 24 months for a total of $32,705,550.00 bought. Which Mineralys Therapeutics insiders have been selling company stock? The following insider sold MLYS shares in the last 24 months: David Malcom Rodman ($2,012,335.71). How much insider selling is happening at Mineralys Therapeutics? Insiders have sold a total of 157,091 Mineralys Therapeutics shares in the last 24 months for a total of $2,012,335.71 sold. More Insider Trading Tools from MarketBeat Related Companies: VERV Insider Buying OLMA Insider Buying ATXS Insider Buying KRRO Insider Buying PHAT Insider Buying NUVB Insider Buying LYEL Insider Buying ANAB Insider Buying ZYME Insider Buying SIGA Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: The 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1Michael Burry Picked a Winner With GEN Restaurant Group This page (NASDAQ:MLYS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.